Amerikanische Gesellschaft für Hirudotherapie

Desirudin (Revasc) to prevent thromboembolic complications after hip or knee replacement surgery

Research article published in Therapie (2002)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Clinical trialArzneimittelentwicklungHeiz-Valle C et al. · Therapie, 2002

Abstract

Since March 1999, desirudin (REVASC), a recombinant hirudin, has been used in Nancy to treat patients who undergo total hip or knee replacement with a high risk of thromboembolic complications. We carried out a retrospective study using clinical data on the first 15 consecutive patients treated with desirudin to find out prescription motivations, type of shift (indirect anticoagulants or low-molecular-weight-heparin) and evolution. They all had a high risk of deep vein thrombosis (thrombophily, obesity, history of thromboembolic events). Some of this patients would have been excluded of the studies which permitted desirudin to be approved. In this study, we found no thromboembolic complications. The only striking facts are one bleeding complication (after difficult surgery) and one pulmonary embolism (2 months later).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeClinical TrialJournal Article
Indexed MeSH termsAgedArthroplasty, Replacement, HipArthroplasty, Replacement, KneeFemaleFibrinolytic AgentsHirudin TherapyHirudinsHumansMaleMiddle AgedPostoperative ComplicationsRecombinant Proteins

Zusammenfassung

Desirudin (Revasc) to prevent thromboembolic complications after hip or knee replacement surgery.

Warum dies für die Hirudotherapie relevant ist

This retrospective study examined the first 15 consecutive high-risk patients treated with desirudin, identified in the abstract as a recombinant hirudin, to prevent thromboembolic complications following total hip or knee replacement surgery. The study found no immediate thromboembolic complications but noted one bleeding complication following difficult surgery and one delayed pulmonary embolism occurring two months later. The abstract describes desirudin as a recombinant product and makes no mention of leeches, leech saliva, or hirudotherapy, so no defensible connection to ASH's domain is established. The study is also limited by its very small sample size of 15 patients, which precludes definitive safety or efficacy conclusions.

Zitation

Desirudin (Revasc) to prevent thromboembolic complications after hip or knee replacement surgery

Heiz-Valle C et al. · Therapie, 2002

DOIPubMed

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsHemostasisOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.